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Several population studies have shown that people are quite
well aware of their blood pressure levels and possible
hypertension in many countries. The same does not apply to
cholesterol levels and awareness of hypercholesterolaemia,
although there has been significant improvement in many
countries over the last decade.
The prevalence of hypercholesterolaemia varies considerably
between countries,1–9 as well as within countries, and between
different areas and population groups.8,10–12
In the US, in the late 1980s about 60% of the population over
18 years of age had had their cholesterol measured.11,13 By the
end of the 1990s, the proportion of the population over 20 years
of age whose cholesterol had been measured increased to
70%.14,15 In Sweden, 69% of the population aged 40–49 years
had had its cholesterol measured by the end of the 1980s.16
Several studies have reported that around half of those with
hypercholesterolaemia are aware of their elevated cholesterol
levels. The proportion varies from one-third to two-thirds across
populations.3,6,12,17,18
In Italy and France about half of those aware of their
hypercholesterolaemia were using lipid-lowering drugs.3,17 In
other countries, the prevalence of drug treatment for
hypercholesterolaemia among those aware of their condition
was substantially lower.4,6,17,18
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Background Several studies have been conducted to estimate the population prevalence of
hypertension, or its diagnosis and treatment. There is no multinationally
comparable information on the prevalence of hypercholesterolaemia, or its
diagnosis and treatment, since individual studies are often not directly
comparable.
Methods Data from the WHO MONICA Project’s final risk factor surveys were used. Data
were collected using standardized methods between 1989 and 1997 for the 35–64
year age range in 32 populations, in 19 countries on 3 continents.
Results The prevalence of hypercholesterolaemia (total cholesterol 6.5 mmol/l or
taking lipid-lowering drugs) varied across populations from 3% to 53% in men,
and from 4% to 40% in women. Awareness of hypercholesterolaemia varied
from 1% to 33% in men, and from 0% to 31% in women. In most populations,
over 50% of men and women on lipid-lowering drugs had a cholesterol level
6.5 mmol/l.
Conclusions There is wide variation in the prevalence, awareness, and treatment of
hypercholesterolaemia between populations. For the planning and
implementation of primary prevention programmes and for the development of
health care systems, monitoring of changes, both within and between
populations, is essential. To obtain reliable information on these changes, well-
standardized methods must be applied.
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However important each individual study may be in assessing
specific populations, their value for international comparison is
limited. Individual studies often differ in terms of study
methods: age groups under consideration and data collection
methods can vary, as can the indicator definitions used.
Until now, there have been no large-scale multinational
comparisons of prevalence, awareness, and treatment of
hypercholesterolaemia. The WHO MONICA Project19 provides
unique multinational data, which were collected employing
standardized methods. This paper will use these data from 32
populations, in 19 countries on 3 continents to compare the
prevalence, awareness, and treatment of hypercholesterolaemia
and the frequency of total cholesterol measurement at an
international level.
Methods
Study populations
The WHO MONICA Project20 was carried out in geographically
defined populations. Each centre carried out at least two
population surveys, one at the beginning and another at the
end of the 10-year study period. Most centres also conducted an
optional middle survey.
The questionnaire items on awareness and treatment of
hypercholesterolaemia were introduced into the MONICA
protocol in 1991.21 By that time, all centres had already
conducted their initial surveys and some had started their
middle surveys. That is why the data for awareness and
treatment of hypercholesterolaemia are not available for all
MONICA surveys and why we are only using data from the final
surveys in this paper.
A total of 32 populations, representing 19 countries, included
questions about awareness and treatment of hypercholestero-
laemia and measurement of total cholesterol in their final
surveys. These were conducted between 1989 and 1997, but
predominantly between 1992 and 1995. The response rate was
at least 70% in most populations, with a range of 41–90%
(Table 1)
This paper presents data for men and women separately for
the 35–64 year age group.
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Table 1 Populations, survey periods, and response rates in age group 35–64 years
Response rate
Questionnaire Total cholesterol
Country Population Abbreviation Survey period items measurementa
Australia Newcastle AUS–NEW Jun94–Dec94 63 62
Perth AUS–PER May94–Nov94 74 69
Belgium Charleroi BEL–CHA Jul90–Feb93 61 32
Ghent BEL–GHE Apr90–Apr92 71 50
Canada Halifax County CAN–HAL May95–Nov95 57 46
China Beijing CHN–BEI Sep93–Oct93 70 70
Czech Republic Czech Republic CZE–CZE Mar92–Dec92 77 76
Denmark Glostrup DEN–GLO Feb91–Mar92 74 74
France Lille FRA–LIL Jun95–Nov96 73 72
Strasbourg FRA–STR Mar95–Apr97 41 39
Toulouse FRA–TOU Dec94–Jul96 59 59
Germany Bremen GER–BRE May91–Jun91 68 65
East Germany GER–EGE Sep93–Dec94 58 64
Iceland Iceland ICE–ICE Jun93–Apr94 80 79
Italy Area Brianza ITA–BRI Sep93–Nov94 73 73
Friuli ITA–FRI Mar94–Oct94 77 77
Lithuania Kaunas LTU–KAU Feb92–May93 57 56
Poland Tarnobrzeg Voivodship POL–TAR Jun92–Jul93 75 75
Warsaw POL–WAR Jan93–Dec93 77 76
Russia Moscow Control RUS–MOC Mar92–Mar95 66 65
Moscow Intervention RUS–MOI Jan92–Mar95 76 72
Novosibirsk Control RUS–NOC Jan95–Jun95 70 68
Novosibirsk Intervention RUS–NOI May94–Feb95 73 71
Spain Catalonia SPA–CAT Jun94–May96 74 71
Sweden Gothenburg SWE–GOT Sep94–Feb96 72 66
Northern Sweden SWE–NSW Jan94–Apr94 80 80
Switzerland Ticino SWI–TIC Oct92–May93 76 73
Vaud/Fribourg SWI–VAF Nov92–Jun93 57 56
UK Belfast UNK–BEL Oct91–Dec92 48 46
Glasgow UNK–GLA Feb95–Oct95 58 54
USA Stanford USA–STA Jun89–Jun90 60 57
Yugoslavia Novi Sad YUG–NOS Sep94–Feb95 90 75
a Blood sample taken
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Data collection and quality control
In the WHO MONICA Project, data were collected using
standardized methods and questions.21 Blood samples were
taken by venepuncture and assayed in local laboratories with
central standardization and external quality control. The details
of the standardization of lipid measurements are given in the
MONICA Manual.22
The data quality was assessed and reported in the
retrospective quality assessment reports. Some populations
modified the MONICA protocol to accommodate local needs
and to lend continuity with earlier surveys. All these
differences, data quality and availability, are reported in detail
in the quality assessment reports,23,24 but briefly: for the total
cholesterol measurement, four populations (Perth, Australia,
Kaunas, Lithuania, and Ticino and Vaud/Fribourg, Switzerland)
had major problems in the external quality control. In four
populations (Charleroi and Ghent, Belgium, Glostrup,
Denmark, and Auckland, New Zealand) 4–6% lower total
cholesterol values can be expected, because of venepuncture in
the supine position, instead sitting as in all other populations. In
Perth and Newcastle, Australia, Strasbourg and Toulouse,
France, Tarnobrzeg Voivodship and Warsaw, Poland, and
Stanford, USA, we can expect 3–4.5% lower total cholesterol
values because EDTA-plasma was used for cholesterol
determination instead of serum.23
For the questionnaire items, the data availability was at
least 90% for those who were surveyed in most of the
populations.24
Definitions
The following definitions of indicators are used in this paper:
Hypercholesterolaemia
Total cholesterol 6.5 mmol/l or using lipid-lowering drugs.
(Several other definitions were also considered using alternative
cut-points [5.0 mmol/l and 6.2 mmol/l] and whether or not an
individual was on lipid-lowering medication.)
Awareness of hypercholesterolaemia
A doctor or other health care worker had told that the subject
had elevated total cholesterol.
On drug treatment
During the past 2 weeks had taken medicine prescribed by a
doctor to lower blood cholesterol.
On dietary treatment
Were on the special diet prescribed by a doctor or other health
care worker to lower blood cholesterol.
On drug and dietary treatment
During the past 2 weeks having taken prescribed medicine and
on a diet to lower blood cholesterol.
Controlled hypercholesterolaemia
Used lipid-lowering drugs and had total cholesterol
6.5 mmol/l.
Statistical methods
Reported prevalences were age standardized according to the
World standard population weights.25 Correlations between
different indicators were calculated from population
prevalences.
Results
Prevalence of hypercholesterolaemia
The prevalence of hypercholesterolaemia depends on the
population mean total cholesterol (Table 2), distribution curve
of total cholesterol in the population and the chosen definition
(Figure 1).
The difference in the prevalence of hypercholesterolaemia
within populations was on average 48 percentage points when
comparing the prevalence defined as total cholesterol
6.5 mmol/l or using lipid-lowering drugs, with the prevalence
defined as total cholesterol 5.0 mmol/l. In men, in Toulouse,
France the variation was up to 60 percentage points (Figure 1).
The prevalence of hypercholesterolaemia (total cholesterol
6.5 mmol/l) in men was on average 27%, being lowest in
Beijing, China (2%), and highest in Ticino, Switzerland (51%).
The prevalence was below 10% in Beijing, China and in
Novosibirsk Control, Russia, over 10% but less than 30% in 18
populations and over 30% in 12 populations (Figure 1).
In women, the prevalence of hypercholesterolaemia was on
average 25%, again being lowest in Beijing, China (3%), and
highest in Novi Sad, Yugoslavia (40%). The prevalence was below
10% only in Beijing, China, over 10% but not more than 30% in
21 populations and over 30% in 10 populations (Figure 1).
When taking lipid-lower drug treatment into account in the
definition of hypercholesterolaemia (6.5 mmol/l), the
prevalence increased on average by 1% in both men and
women (Figure 1).
There was no clear geographical pattern to the prevalence of
hypercholesterolaemia in men or women.
Frequency of total cholesterol measurement
On average, 30% of men had had their cholesterol measured in
the past year. There were big differences in the frequency of
cholesterol measurement during the past year between
populations. In Moscow Control, Russia, only 2% of men had
had their cholesterol measured in the past year, while in
Bremen, Germany, the frequency was 57%. The frequency was
on average 37% in men with hypercholesterolaemia (Figure 2).
In women, the frequency of cholesterol measurement during
the past year was similar to that in men (on average 30%) but
there was a little wider variation between populations. The
lowest frequency was in Moscow Control, Russia (2%), and
the highest in Toulouse, France, and Bremen, Germany (59%).
The frequency of cholesterol measurement among women with
hypercholesterolaemia remained about the same as in the
entire population, running on average at 38% (Figure 2).
Some geographical patterns in the frequency of cholesterol
measurements emerged. The highest frequency was observed
in France, Belgium, Germany, Italy, and Spain in both men
and women, while the lowest were seen in Russia and
Lithuania.
Awareness of hypercholesterolaemia
On average 19% of men in all populations were aware of their
hypercholesterolaemia. There was large variation between
populations: from 1% in Kaunas, Lithuania to 33% in
Strasbourg, France, and in Bremen, Germany. The prevalence
of awareness, on average 36%, was much higher among men
with hypercholesterolaemia, varying from 3% in Kaunas,
Lithuania, to 62% in Catalonia, Spain (Figure 3).
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Table 2 Correlation coefficients between different age-standardized prevalences for men (top triangle) and women (bottom triangle) in age group 35–64
Cholesterol 
Cholesterol measured during Awareness
measured the  past year among people
during the among people with with hyperc- Combined drug Controlled Mean total
past year in hypercholester- Awareness in holestero- Drug treat- Dietary treat- and dietary hypercholes- Hypercholes- cholesterol
population olaemia population laemia ment only ment only treatment terolaemia terolaemiaa (mmol/l)
Cholesterol measured ** 0.95 0.91 0.82 0.30 0.08 0.12 0.04 0.39 0.34
during the past year 
in population
Cholesterol measured 0.96 ** 0.84 0.75 0.27 0.18 0.12 0.03 0.26 0.30
during the past year
among people with
hypercholesterolaemia
Awareness in 0.92 0.88 ** 0.92 0.33 0.12 0.08 0.08 0.49 0.39
population
Awareness among 0.84 0.88 0.88 ** 0.57 0.06 0.22 0.28 0.19 0.02
people with
hypercholesterolaemia
Drug treatment only 0.16 0.26 0.16 0.44 ** 0.20 0.25 0.49 0.09 0.43
Dietary treatment only 0.06 0.01 0.09 0.01 0.36 ** 0.12 0.06 0.07 0.12
Combined drug and 0.14 0.05 0.17 0.13 0.02 0.11 ** 0.30 0.25 0.44
dietary treatment
Controlled 0.24 0.09 0.19 0.06 0.12 0.06 0.30 ** 0.18 0.45
hypercholesterolaemia
Hypercholesterolaemiaa 0.13 0.02 0.14 0.14 0.47 0.36 0.26 0.07 ** 0.91
Mean total cholesterol 0.07 0.02 0.08 0.24 0.66 0.41 0.22 0.07 0.82 **
(mmol/l)
a Total cholesterol  6.5 mmol/l or using lipid-lowering drugs.
On average 17% of females in all populations were aware of
their hypercholesterolaemia, varying from 0% in Novosibirsk
Intervention, Russia to 31% in Bremen, Germany. The
prevalence of awareness was substantially higher in most
populations among women with hypercholesterolaemia. The
lowest prevalence was seen in Novosibirsk Intervention in Russia
(0%) and the highest in Toulouse, France (65%) (Figure 3).
The highest awareness among people with hypercholestero-
laemia was in populations in Spain, France, Belgium, Germany,
Italy, and North America and, in men, also in Australia. The
awareness was lowest in Lithuania and Russia.
Treatment of hypercholesterolaemia
In men with hypercholesterolaemia, from 0% to 100% were
using either lipid-lowering drugs or were on special diets to
lower their blood cholesterol, or both. On average, 45% of men
with hypercholesterolaemia were using some kind of treatment.
The prevalence of drug treatment alone was on average 8%,
being lowest in Russia, Lithuania, USA, and Denmark (0%) and
highest in Beijing, China (41%), and France (20–28%). The
prevalence of dietary treatment alone was on average 23%,
being lowest in Novosibirsk Control, Russia (0%) and highest in
Warsaw, Poland (46%), and Iceland (42%). The prevalence of
combined drug and dietary treatment was on average 14%,
varying from 0% in Moscow and Novosibirsk Controls, Russia,
and in Kaunas, Lithuania, to 48% in Novosibirsk Intervention,
Russia (Table 3).
In women with hypercholesterolaemia, on average 44%
were using some kind of treatment to lower their blood
cholesterol, ranging from 0% in Novosibirsk Intervention to
91% in Moscow Intervention, Russia. The prevalence of drug
treatment alone was on average 6%, varying from 0% in
Russia, Lithuania, Iceland, and Ghent, Belgium to 37% in
China. The prevalence of dietary treatment alone, on average
24%, was lowest in China and Novosibirsk Intervention in
Russia (0%) and the highest in Lithuania (72%). The
prevalence of combined drug and dietary treatment on average
was 14%, varying from 0% in Novosibirsk Intervention to 79%
in Moscow Intervention, Russia (Table 3).
There was no clear geographical pattern to the prevalence of
drug or dietary treatment, singly or in combination, in men
or women.
Controlled hypercholesterolaemia
The proportion of those with total cholesterol below the desired
level (6.5 mmol/l) among lipid-lowering drug users was on
average 61% in men, varying from 18% in Vaud/Fribourg,
Switzerland to 100% in Beijing, China and Moscow Control,
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Figure 1 The age-standardized prevalence of hypercholesterolaemia for men and women in age group 35–64
Russia. In both Beijing and Moscow Control the number of
people using lipid-lowering drugs was very low, seven in Beijing
and only one in Moscow Control. In most populations (17 out
of 32), the proportion was at least 50% but less than 100%
(Table 3).
In women, the proportion was on average 65% and varied
from 0% in Glostrup, Denmark, to 100% in Moscow and
Novosibirsk Controls, Russia. In Glostrup, only two women
were using lipid-lowering drugs and neither of them had total
cholesterol 6.5 mmol/l. In both Moscow and Novosibirsk
Controls, only one woman was using lipid-lowering drugs. The
proportion was at least 50% but less than 100% in the majority
(19 out of 32) of populations (Table 3).
There was no evident geographical pattern to controlled
hypercholesterolaemia in either men or women.
Relationships between prevalences
In men, the prevalence of the awareness of hypercholestero-
laemia was high in populations where the prevalence of
cholesterol measurement was also high (r = 0.91). The same
pattern was seen among hypercholesterolaemics (r = 0.86). At
the population level, there was a positive correlation between
the frequency of cholesterol measurement and the prevalence
of hypercholesterolaemia (r = 0.39) (Table 2).
The prevalence of awareness of hypercholesterolaemia
among men with hypercholesterolaemia was positively
correlated with the prevalence of drug treatment (r = 0.57). The
prevalence of awareness in the population was also positively
correlated with the prevalence of hypercholesterolaemia
(r = 0.49) (Table 2).
In men, the prevalence of controlled hypercholesterolaemia
was positively correlated with the prevalence of drug treatment
(r = 0.49). The prevalence of treatment (drugs, diet, or
combination of drugs and diet) showed no correlation with the
prevalence of hypercholesterolaemia (Table 2).
In women, the prevalence of awareness of hypercholestero-
laemia was strongly correlated with the frequency of cholesterol
measurement (r = 0.92). An equally strong correlation was
observed in women with hypercholesterolaemia (Table 2).
The prevalence of the awareness of hypercholesterolaemia in
women with hypercholesterolaemia was positively correlated
with the prevalence of drug treatment (r = 0.44) (Table 2).
In women, the prevalence of combined drug and diet
treatment was positively correlated with the prevalence of
controlled hypercholesterolaemia (r = 0.30). The prevalence of
hypercholesterolaemia was negatively correlated with drug
treatment (r = 0.47) but positively correlated with the
prevalence of dietary treatment (r = 0.36) (Table 2).
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Figure 2 The age-standardized prevalence of cholesterol measurement for men and women in age group 35–64
Discussion
Methodological issues
Information about the prevalence, awareness, and treatment of
hypercholesterolaemia, and the proportions of populations,
who had had their cholesterol measured during the past year,
can be collected through population surveys. Some information
on the prevalence of hypercholesterolaemia and its treatment
can also be assembled from routine medical records. The use of
medical (or pharmacy) records is not possible in multinational
studies as the coverage, availability, and data access regulations
vary greatly.
Several validation studies of questionnaires collecting health
information have been published but in only a few has the
validity of awareness of hypercholesterolaemia been
assessed.26–28 The sensitivity for awareness of hypercholestero-
laemia, has been reported to be 75–80%27,28 and the specificity
75–90%.26–28 Although some studies have reported lower
sensitivities26 and specificities.27
The validity of prescription drug use can be assessed by
comparing self-reported data with pharmacy or medical records.
Several such studies have been conducted but they have rarely
included lipid-lowering drugs.29 Generally, the agreement
between self-reported use of prescription drugs and medical or
pharmacy records is high, even though there are differences
between drug classes.29–31 The sensitivity for self-reported lipid
lowering drugs is said to lie between 85% and 100%.29,32
Based on this information we can assume that the results from
MONICA are fairly reliable and reflect the true situation in
the populations.
MONICA asked whether a person had ever been told that
he/she had high cholesterol. It may be difficult for respondents
to remember what a doctor has told them about their
cholesterol levels several years earlier. It has been documented
that the degree of recall bias increases with the length of the
recall period.33 From the monitoring standpoint, it would be
more interesting to know how many people have been told by
their doctor in the past year or 5 years that they have elevated
cholesterol. This would also reduce recall bias and give more
up-to-date information about awareness of hypercholestero-
laemia in the population.
The formulation of questions used to obtain medical treatment
information may affect the findings. When medical treatment is
studied using specific questions like ‘Are you currently taking
medication prescribed by a doctor to lower your blood
cholesterol level?’, the prevalence is usually lower than if the
question simply asks for all medications to be listed.34 In all
MONICA populations, the question about cholesterol-lowering
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Figure 3 The age-standardized prevalence of awareness of hypercholesterolaemia for men and women in age group 35–64
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Table 3 Mean total cholesterol (mmol/l), prevalence of hypercholesterolaemia, different treatments among people with hypercholesterolaemia, and controlled hypercholesterolaemia. Age group
35–64, age-standardized
Men Women
Hypercholesterolaemiaa Hypercholesterolaemiaa
Mean total Treatment
b
Mean total Treatment
b
cholesterol Diet + cholesterol Diet +
Population (mmol/l) % n Drugs Drugs Diet None Controlled (mmol/l) % n Drugs Drugs Diet None Controlled
AUS–NEW 5.76 30 184 22 7 9 63 66 5.58 20 171 9 7 14 71 51
AUS–PER 5.57 20 121 19 8 1 72 90 5.45 20 129 24 5 4 67 83
BEL–CHA 6.18 40 96 14 8 26 52 93 6.1 30 74 1 6 23 70 95
BEL–GHE 6.03 33 121 3 19 39 39 54 5.96 32 101 0 12 31 58 71
CAN–HAL 5.64 23 48 7 29 15 49 82 5.77 27 64 1 9 48 42 72
CHN–BEI 4.52 3 16 41 21 39 0 100 4.49 4 28 37 8 0 55 88
CZE–CZE 6.17 38 334 6 15 30 49 53 6.14 37 355 1 5 35 60 75
DEN–GLO 5.96 30 187 0 10 32 58 42 5.82 26 175 2 13 27 58 0
FRA–LIL 5.4 36 211 20 42 13 25 67 5.82 28 182 11 29 18 42 67
FRA–STR 6.03 40 214 20 19 15 46 63 5.91 34 193 17 23 16 44 35
FRA–TOU 5.82 32 201 28 31 9 32 77 5.65 26 168 22 22 17 39 84
GER–BRE 6.15 36 262 2 7 36 56 55 6.16 37 287 0 6 30 64 39
GER–EGE 6.05 29 120 9 25 14 52 60 5.85 23 122 3 18 15 64 31
ICE–ICE 6.16 36 255 3 8 42 47 46 6.03 31 239 0 13 29 58 84
ITA–BRI 5.93 28 186 4 14 32 49 27 5.89 26 184 1 12 34 53 57
ITA–FRI 5.87 28 192 3 3 21 73 38 5.66 21 152 5 10 13 71 49
LTU–KAU 5.96 31 178 0c 0c 29 71 0 6.19 40 249 0 14 72 14 100
POL–TAR 5.58 19 100 2 31 32 35 87 5.51 18 117 11 24 38 27 90
POL–WAR 5.75 25 123 5 4 46 46 42 5.65 21 118 3 9 41 47 54
RUS–MOC 5.26 13 71 6 0 9 85 100 5.55 21 110 0 20 7 74 100
RUS–MOI 5.38 16 84 3 22 6 69 79 5.51 21 175 0 79 12 9 88
RUS–NOC 5.01 8 45 0c 0c 0 100 0 5.34 15 79 0 39 12 49 100
RUS–NOI 5.38 15 87 0 48 38 15 48 5.4 16 102 0 0 0 100 0
SPA–CAT 5.61 21 290 3 19 18 60 49 5.53 19 243 2 11 25 62 70
SWE–GOT 5.57 26 158 8 11 39 42 28 5.44 22 164 13 10 19 58 74
SWE–NSW 6.28 45 258 4 5 31 60 94 6.12 35 212 1 2 33 64 75
SWI–TIC 6.54 53 369 13 7 6 74 40 5.19 38 297 6 4 13 76 22
SWI–VAF 6.31 42 231 4 7 5 84 18 6.06 35 189 4 11 11 74 69
UNK–BEL 5.9 27 229 1 8 36 54 57 5.91 31 254 1 3 45 51 33
UNK–GLA 6.05 35 227 4 1 4 90 57 6.08 36 252 1 5 8 86 68
USA–STA 5.4 15 57 0 28 39 33 67 5.31 15 70 10 20 48 23 36
YUG–NOS 6.37 44 200 5 6 20 69 50 6.19 40 218 1 4 26 69 64
Note the year of the survey in Table 1.
a Total cholesterol 6.5 mmol/l and/or using lipid-lowering drugs.
b Among people with hypercholesterolaemia.
c No one using lipid-lowering drugs.
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drugs was specifically asked, so this should not have biased the
comparisons between populations but may have caused some
underestimation of the reported treatment prevalences.
Limitations of the study
Even though the MONICA Project may provide the largest
available standardized multinational dataset on which the
prevalence, awareness, and treatment of hypercholesterolaemia
can be studied, there are some limitations to the use of the data.
The data were collected in early and mid 1990s. Over the last
decade, treatment practices for hypercholesterolaemia have
changed markedly, especially since the introduction of statins.
Current prevention guidelines recommend starting patients on
cholesterol-lowering drugs at total cholesterol levels as low as
5.0 mmol/l if they are considered to be at high multifactorial
risk of developing coronary heart disease (CHD).35
We have employed cut-points in order to categorize the data
for presentation in this paper. We recognize that this may be
misleading as the risk associated with total cholesterol tends to
be continuous, and, as we have seen, the cut-points
recommended are constantly being reduced.
In comparing results from cross-sectional studies, it would be
better to have all surveys in the different populations conducted
simultaneously. In the MONICA Project, most surveys were
conducted within a few years, but some were separated by up
to eight years.
In few populations, the low overall response rate or low data
availability of some items may have biased the results. If it is
assumed that survey respondents and non-respondents are
similar, then there would be no bias, even in those populations
with low response rates. Unfortunately, there is evidence that
non-respondents usually manifest unhealthier lifestyles and
health profiles.36–38
In some MONICA populations, the phrase ‘prescribed by a
doctor’ was omitted from the question(s) on the drug treatment
of hypercholesterolaemia. This may have caused slight
overestimation of treatment prevalence as respondents may
have reported the use of medications other than specific lipid-
lowering drugs, such as herbal substances.
Prevalence of hypercholesterolaemia
In general, populations with low mean total cholesterol levels
have lower prevalences of hypercholesterolaemia than
populations with high mean total cholesterol levels. However,
the population mean total cholesterol levels are not the sole
determinants of the prevalence of hypercholesterolaemia.
Additionally, the shape of the total cholesterol distribution has
a significant effect on the prevalence of hypercholesterolaemia,
and the treatment practice for hypercholesterolaemia, which
may vary between populations. The diverse treatment practices
do not explain the differences between population prevalences
in our study, since adding those using lipid-lowering drugs only
increased the prevalence of hypercholesterolaemia by 1%.
Depending on the definition of hypercholesterolaemia used,
the prevalence varied substantially within populations. This
emphasizes the importance of a uniform definition of
hypercholesterolaemia when the results from more than one
study are compared.
The wide variations in the prevalences of hypercholestero-
laemia between populations cannot be explained by poor data
quality since the populations with quality problems did not
cluster at either end of the distribution.
Awareness of hypercholesterolaemia and
measurement of total cholesterol
The awareness of hypercholesterolaemia correlated strongly
with the prevalence of total cholesterol measurement in the
population, which seems self-evident. Some believe that
everyone should have their total cholesterol measured every
5 years. To fulfil this goal would require huge financial
investment and is unrealistic. In every day practice, it would be
equally as important to identify those at high multifactorial risk
of cardiovascular disease and to treat them.
Increasing the frequency of cholesterol screenings will not in
itself reduce the prevalence of hypercholesterolaemia, as our
results indicate. In those populations with the highest
prevalence of hypercholesterolaemia, the prevalence of
cholesterol measurement during the past year was also amongst
the highest.
Treatment of hypercholesterolaemia
The prevalence of the medical treatment of hypercholestero-
laemia is very low in most populations, even among those
aware of their hypercholesterolaemia. Increasing the frequency
of drug treatment of hypercholesterolaemia will require
much effort to even approach the level of treatment for
hypertension.39
The prevalence of drug treatment is strongly correlated with
the frequency of screening, which would support the need of
screenings to detect hypercholesterolaemia in the population.
Comparison with prevention recommendations
The European Guidelines on Cardiovascular Disease Prevention
in Clinical Practice in 1994,40 1998,41 and 200335 have set out
primary and secondary prevention targets and practical
guidelines. Since the CHD is a multifactorial disease, total
cholesterol should not be considered in isolation when treating
the patient. In general, the goal for total cholesterol levels is
5.0 mmol/l.35 In our study, only Beijing, China, had more
than 50% of its populations with total cholesterol 5.0 mmol/l.
When the data for this study were collected, the level of total
cholesterol at which the risk of CHD rapidly increased was
considered to be 6.5 mmol/l.40 Applying this cut-point in all our
study populations, the prevalence of drug treatment among
people with hypercholesterolaemia (total cholesterol 6.5 mmol/l
or using lipid-lowering drugs) would have appeared extremely
low. In those on treatment, the cholesterol level was
6.5 mmol/l in the majority of populations, i.e. more than 50%
of those treated were controlled.
Conclusions
There is wide variation between populations in the prevalence,
awareness and treatment of hypercholesterolaemia. There is
also a clear relationship between screening frequency for
cholesterol and the awareness and treatment of hypercho-
lesterolaemia across populations.
Even though the frequency of cholesterol measurement is
strongly correlated with the awareness and treatment of
hypercholesterolaemia at the population level, it is more
important to focus existing financial resources on primary
prevention in those at high risk, and on secondary prevention,
than on screening entire populations.
Information on the prevalence of hypercholesterolaemia, its
treatment in people with hypercholesterolaemia and their
awareness is also important in the planning and
implementation of primary prevention programmes and the
development of health care systems.
In order to monitor changes within and between populations,
standardization of methods is essential. As this kind of
information can only be collected through population surveys,
special attention must be paid to the standardization of total
cholesterol measurement and the questions assessing awareness
and treatment of hypercholesterolaemia.
The WHO MONICA Project is an example of a well-
standardized study in which results between populations and
over time are comparable. Since MONICA was conducted, the
survey methodology has advanced: see, for example, the new
standardized methods recommended by the European Health
Risk Monitoring Project (http://www.ktl.fi/ehrm/).42
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